SR One Capital Management, LP
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 13, 2024), SR One Capital Management, LP reported 9 stock positions worth $319.4 million. Its top holding was Arcellx (ACLX) at 40.5% of the portfolio, followed by Crispr Therapeutics (CRSP, 17.7%) and Ars Pharmaceuticals (SPRY, 10.7%). Compared with Q1 2024, it opened 3 new positions. The biggest buy was a new position in Alumis (ALMS).
- Most Recent 13F
- Q2 2026
- Location
- Redwood City, CA
- CIK
- 0001910264
- Portfolio Value
- $319.4M (Q2 2024)
- SEC Filing
- 0000950123-24-008225 ↗ filed Aug 13, 2024
Holdings Value
Holdings 9 stocks · $319.4M
| ACLX Arcellx Inc. | 40.55% | 2,346,630 | $129.5M | No change |
| CRSP Crispr Therapeutics AG | 17.74% | 1,048,951 | $56.7M | No change |
| SPRY Ars Pharmaceuticals Inc. | 10.69% | 4,012,903 | $34.1M | No change |
| ALMS Alumis Inc. | 8.16% | 1,959,896 | $26.1M | New |
| MLYS Mineralys Therapeutics Inc. | 7.39% | 2,016,822 | $23.6M | No change |
| DSGN Design Therapeutics Inc. | 6.85% | 6,526,476 | $21.9M | No change |
| NKTX Nkarta Inc. | 6.17% | 3,333,333 | $19.7M | No change |
| ENGN Engene Holdings Inc. | 1.48% | 500,000 | $4.7M | New |
| KALA Kala Bio Inc. | 0.98% | 443,661 | $3.1M | New |
Portfolio Sells Q1 2024 → Q2 2024
| None this quarter. | |||
Portfolio Buys Q1 2024 → Q2 2024
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 15 | $1.0B | MANE, ZBIO, CRSP, AVLN, DSGN |
| Q1 2026 | 14 | $915.4M | ACLX, MANE, ZBIO, CRSP, DSGN |
| Q4 2025 | 13 | $706.4M | ZBIO, ACLX, CRSP, DSGN, MLYS |
| Q3 2025 | 12 | $691.4M | ACLX, CRSP, ZBIO, MLYS, ORIC |
| Q2 2025 | 13 | $461.4M | ACLX, SPRY, CRSP, ZBIO, ORIC |
| Q1 2025 | 12 | $389.3M | ACLX, SPRY, MLYS, ZBIO, CRSP |
| Q4 2024 | 11 | $410.1M | ACLX, SPRY, CRSP, DSGN, ZBIO |
| Q3 2024 | 11 | $498.7M | ACLX, ZBIO, SPRY, CRSP, DSGN |
| Q2 2024 | 9 | $319.4M | ACLX, CRSP, SPRY, ALMS, MLYS |
| Q1 2024 | 6 | $364.1M | ACLX, CRSP, SPRY, NKTX, DSGN |